Lonza's Synaffix and Qurient Therapeutics Unite for Innovative ADC Development
In a groundbreaking collaboration, Synaffix B.V., a subsidiary of Lonza, has formed a licensing agreement with South Korea's Qurient Co., Ltd. The partnership aims to advance the development of dual-payload antibody-drug conjugates (ADCs), a cutting-edge approach designed to tackle cancer more effectively. The unique technology combines Synaffix's exatecan-based platform with Qurient's CDK7 inhibitor, creating a novel solution to treat solid tumors that presently lack effective therapies.
Understanding Dual-Payload ADCs
Dual-payload ADCs stand out because they can transfer two distinct cytotoxic agents to target cancer cells. This innovative design not only promises enhanced therapeutic efficacy but also aims to reduce the chance of resistance to treatment. Especially beneficial for patients with refractory cancers, the dual approach offers a new beacon of hope by minimizing damage to healthy cells while maximizing therapeutic potential.
Under the terms of the licensing agreement, Qurient will utilize Synaffix's clinical-stage ADC technology, which includes their advanced GlycoConnect® antibody conjugation method, along with HydraSpace® polar spacer and exatecan-based linker-payload technologies. This partnership allows Qurient access to Synaffix’s cutting-edge technology and Lonza's extensive expertise in bioconjugate development and manufacturing.
As part of this collaboration, Lonza will handle the production of essential components related to its patented Synaffix technologies, while Qurient is tasked with the research, development, and commercialization phases of the ADC. They will also produce Qurient's CDK7 inhibitor within this venture.
Vision Statements from Leadership
Peter van de Sande, the Head of Synaffix, expressed excitement about the partnership, stating, “This licensing collaboration with Qurient signifies the versatility of our industry-leading ADC platform technology. Enabling the development of a dual-payload ADC built with Synaffix technology reflects our drive to pioneer innovation in the field.” He further emphasized that this collaboration is a testament to the capability of their technology to address unmet medical needs.
Kiyean Nam, CEO of Qurient, echoed this sentiment, remarking, “Dual-payload ADCs represent the next frontier in targeted antibody therapeutics. We look forward to advancing this novel combination of our CDK7 inhibitor and Synaffix's SYNtecan™ linker-payload. This combination presents opportunities for a wider range of targets and antibodies, and we are eager to explore these possibilities.”
About the Companies
Synaffix B.V. is a biotechnology company that specializes in developing ADC products through its clinical-stage technology platform. This platform includes features like GlycoConnect®, HydraSpace®, and toxSYN® technologies, which allow companies with antibodies to create best-in-class ADC products under a single license. Their rapid timeline to clinic is supported by an established supply chain of technology components and a solid patent portfolio.
On the other hand, Lonza is recognized as one of the largest development and manufacturing organizations globally, providing services across five continents. In 2025, it boasted impressive sales figures, demonstrating its prominent role in turning groundbreaking pharmaceutical innovations into viable therapies.
Finally, Qurient Co., Ltd. is a publicly-listed biotechnology firm, committed to developing innovative medicines across oncology and infectious disease fields. The company’s existing pipeline illustrates its dedication to tackling high-unmet-need indications. Their strategic focus merges precision oncology with advancements in treating drug-resistant infections, marking it as an important player in medical research.
As these two powerful companies combine their efforts, the collaboration represents not only a step forward in cancer treatment but also signals the potential for significant advancements in therapeutic strategies. This partnership exemplifies the drive and commitment both Synaffix and Qurient have to change the landscape of cancer therapies for patients in need.
Understanding Dual-Payload ADCs
Dual-payload ADCs stand out because they can transfer two distinct cytotoxic agents to target cancer cells. This innovative design not only promises enhanced therapeutic efficacy but also aims to reduce the chance of resistance to treatment. Especially beneficial for patients with refractory cancers, the dual approach offers a new beacon of hope by minimizing damage to healthy cells while maximizing therapeutic potential.
Under the terms of the licensing agreement, Qurient will utilize Synaffix's clinical-stage ADC technology, which includes their advanced GlycoConnect® antibody conjugation method, along with HydraSpace® polar spacer and exatecan-based linker-payload technologies. This partnership allows Qurient access to Synaffix’s cutting-edge technology and Lonza's extensive expertise in bioconjugate development and manufacturing.
As part of this collaboration, Lonza will handle the production of essential components related to its patented Synaffix technologies, while Qurient is tasked with the research, development, and commercialization phases of the ADC. They will also produce Qurient's CDK7 inhibitor within this venture.
Vision Statements from Leadership
Peter van de Sande, the Head of Synaffix, expressed excitement about the partnership, stating, “This licensing collaboration with Qurient signifies the versatility of our industry-leading ADC platform technology. Enabling the development of a dual-payload ADC built with Synaffix technology reflects our drive to pioneer innovation in the field.” He further emphasized that this collaboration is a testament to the capability of their technology to address unmet medical needs.
Kiyean Nam, CEO of Qurient, echoed this sentiment, remarking, “Dual-payload ADCs represent the next frontier in targeted antibody therapeutics. We look forward to advancing this novel combination of our CDK7 inhibitor and Synaffix's SYNtecan™ linker-payload. This combination presents opportunities for a wider range of targets and antibodies, and we are eager to explore these possibilities.”
About the Companies
Synaffix B.V. is a biotechnology company that specializes in developing ADC products through its clinical-stage technology platform. This platform includes features like GlycoConnect®, HydraSpace®, and toxSYN® technologies, which allow companies with antibodies to create best-in-class ADC products under a single license. Their rapid timeline to clinic is supported by an established supply chain of technology components and a solid patent portfolio.
On the other hand, Lonza is recognized as one of the largest development and manufacturing organizations globally, providing services across five continents. In 2025, it boasted impressive sales figures, demonstrating its prominent role in turning groundbreaking pharmaceutical innovations into viable therapies.
Finally, Qurient Co., Ltd. is a publicly-listed biotechnology firm, committed to developing innovative medicines across oncology and infectious disease fields. The company’s existing pipeline illustrates its dedication to tackling high-unmet-need indications. Their strategic focus merges precision oncology with advancements in treating drug-resistant infections, marking it as an important player in medical research.
As these two powerful companies combine their efforts, the collaboration represents not only a step forward in cancer treatment but also signals the potential for significant advancements in therapeutic strategies. This partnership exemplifies the drive and commitment both Synaffix and Qurient have to change the landscape of cancer therapies for patients in need.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.